JPMorgan Chase & Co. Decreases Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)

JPMorgan Chase & Co. decreased its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 17.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 219,568 shares of the biopharmaceutical company's stock after selling 47,311 shares during the period. JPMorgan Chase & Co. owned 0.45% of Theravance Biopharma worth $2,066,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Theravance Biopharma during the fourth quarter worth about $69,000. Teacher Retirement System of Texas purchased a new position in Theravance Biopharma during the 4th quarter worth approximately $103,000. SG Americas Securities LLC increased its position in Theravance Biopharma by 21.1% during the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company's stock worth $181,000 after buying an additional 3,349 shares during the period. Magnetar Financial LLC lifted its stake in Theravance Biopharma by 125.8% in the fourth quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock valued at $259,000 after buying an additional 15,328 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Theravance Biopharma by 279.9% in the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company's stock valued at $529,000 after acquiring an additional 48,316 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Stock Performance

Theravance Biopharma stock traded up $0.27 during mid-day trading on Wednesday, reaching $9.77. 239,693 shares of the company were exchanged, compared to its average volume of 279,889. The firm has a market cap of $488.51 million, a PE ratio of -9.67 and a beta of 0.14. The firm's 50-day simple moving average is $9.10 and its two-hundred day simple moving average is $9.22. Theravance Biopharma, Inc. has a twelve month low of $7.44 and a twelve month high of $10.90.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). The firm had revenue of $18.75 million during the quarter, compared to analysts' expectations of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. As a group, equities research analysts anticipate that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Theravance Biopharma presently has a consensus rating of "Hold" and a consensus target price of $11.33.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of the firm's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 370,038 shares in the company, valued at $3,330,342. This trade represents a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.90% of the company's stock.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.